CD11b
gastrointestinal neoplasms
immune evasion
immunotherapy
myeloid-derived suppressor cells
tumor escape
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
18
06
2021
entrez:
15
7
2021
pubmed:
16
7
2021
medline:
12
1
2022
Statut:
ppublish
Résumé
Tumor metastasis is the major cause of death of colorectal cancer (CRC), and metastatic CRC remains incurable in many cases despite great advances in genetic and molecular profiling, and clinical development of numerous drugs, including immune checkpoint inhibitors. Thus, more effective treatments are urgently needed for the patients in clinical settings. We used mouse CRC metastasis models that murine Colon26 cells were subcutaneously and intravenously implanted and attempted to elucidate the tumor biological and immunological mechanisms underlying cancer metastasis. Then, we evaluated in vivo antitumor efficacy induced by agents targeting the identified molecular mechanisms using the mouse models. We validated the clinical relevancy of the findings using peripheral blood mononuclear cells obtained from stage IV metastatic CRC patients. CD11b The CD11b
Sections du résumé
BACKGROUND
Tumor metastasis is the major cause of death of colorectal cancer (CRC), and metastatic CRC remains incurable in many cases despite great advances in genetic and molecular profiling, and clinical development of numerous drugs, including immune checkpoint inhibitors. Thus, more effective treatments are urgently needed for the patients in clinical settings.
METHODS
We used mouse CRC metastasis models that murine Colon26 cells were subcutaneously and intravenously implanted and attempted to elucidate the tumor biological and immunological mechanisms underlying cancer metastasis. Then, we evaluated in vivo antitumor efficacy induced by agents targeting the identified molecular mechanisms using the mouse models. We validated the clinical relevancy of the findings using peripheral blood mononuclear cells obtained from stage IV metastatic CRC patients.
RESULTS
CD11b
CONCLUSIONS
The CD11b
Identifiants
pubmed: 34261702
pii: jitc-2021-002841
doi: 10.1136/jitc-2021-002841
pmc: PMC8280900
pii:
doi:
Substances chimiques
CD11 Antigens
0
CTLA-4 Antigen
0
Ctla4 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: No, there are no competing interests.
Références
Cancer Lett. 2017 Aug 10;401:39-45
pubmed: 28527945
Signal Transduct Target Ther. 2020 Aug 25;5(1):166
pubmed: 32843638
Gastroenterology. 2020 Jan;158(2):368-388
pubmed: 31563626
Rev Physiol Biochem Pharmacol. 2020 Oct 17;:
pubmed: 33074407
Hosp Pharm. 2020 Jun;55(3):168-180
pubmed: 32508354
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2016 Mar 15;7(11):13060-8
pubmed: 26918337
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
Stem Cells Int. 2017;2017:1656053
pubmed: 28883835
Oncotarget. 2017 Feb 21;8(8):13703-13715
pubmed: 28099147
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Cell Res. 2020 Apr;30(4):285-299
pubmed: 31974523
J Hematol Oncol. 2018 Oct 11;11(1):125
pubmed: 30305116
Nat Rev Drug Discov. 2019 Nov;18(12):899-900
pubmed: 31780841
Cell Death Dis. 2020 Feb 6;11(2):105
pubmed: 32029741
Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G747-56
pubmed: 16373427
Int J Mol Sci. 2018 Aug 07;19(8):
pubmed: 30087255
Biochim Biophys Acta Mol Basis Dis. 2020 Apr 1;1866(4):165339
pubmed: 30481586
J Clin Invest. 2018 Aug 1;128(8):3209-3218
pubmed: 30067248
J Clin Oncol. 2017 Jun 1;35(16):1836-1844
pubmed: 28406723
J Clin Invest. 2015 Sep;125(9):3347-55
pubmed: 26325032
Front Immunol. 2020 May 15;11:783
pubmed: 32508809
Cell Death Discov. 2016 Apr 04;2:16019
pubmed: 27551512
J Natl Cancer Inst. 2014 Nov 27;107(1):345
pubmed: 25432409
Front Immunol. 2019 Jun 20;10:1412
pubmed: 31281320
Int J Mol Sci. 2018 Aug 08;19(8):
pubmed: 30096840
Cancer Cell. 2009 Mar 3;15(3):195-206
pubmed: 19249678
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Trends Immunol. 2015 Apr;36(4):265-76
pubmed: 25797516
Immunity. 2020 Dec 15;53(6):1215-1229.e8
pubmed: 33220234
Trends Cell Biol. 2020 Oct;30(10):764-776
pubmed: 32800658
BMC Cancer. 2020 Jul 9;20(1):638
pubmed: 32646396
Oncotarget. 2018 Mar 30;9(24):16665-16677
pubmed: 29682176
MAbs. 2010 Jan-Feb;2(1):3-13
pubmed: 20065636
J Cell Biochem. 2018 Aug;119(8):7040-7052
pubmed: 29737564
Cancers (Basel). 2021 Jan 26;13(3):
pubmed: 33530653
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601415
Front Immunol. 2019 Aug 21;10:1999
pubmed: 31552017
Stem Cells Dev. 2016 May 15;25(10):774-87
pubmed: 26979751
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690